MenD 2: Michigan Men's Diabetes Project 2

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05370781
Collaborator
(none)
60
1
2
26
2.3

Study Details

Study Description

Brief Summary

The Michigan Men's Diabetes Project 2 (MenD 2) is an 18-month pilot randomized clinical trial. We are looking to recruit 60 Black men with type 2 diabetes (need to have diagnosis for at least 6 months) that are over the age of 21. Interested participants need to be under the care of a physician for their diabetes, have access to reliable transportation for study activities, and be willing to participate in 4 health assessments where they will get their A1C, blood pressure, height, and weight measured and they will complete a survey. All participants will receive 10 hours of diabetes self-management education with a Certified Diabetes Care and Education Specialist. Participants randomized to the intervention arm will also be offered 6 months of monthly diabetes self-management support (DSMS) sessions with trained Peer Leaders who are also Black men with type 2 diabetes. After the 6 months of support, this group will transition into 6 months of ongoing support where they can continue DSMS and/or other diabetes related initiatives that are important to the group and chosen by the group. Due to the COVID-19 pandemic, DSME and DSMS sessions will likely be held via Zoom, ongoing support sessions have potential to be in person. The 4 health assessments will take place at baseline, 3-months, 9-months, and 15-months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Peer Led Diabetes Self-Management Support
  • Behavioral: Diabetes Self-Management Education
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Michigan Men's Diabetes Project 2
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Peer led diabetes self-management support (PLDSMS)

Participants in the PLDSMS arm will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist. This group will then transition into monthly 90-minute diabetes self-management support (DSMS) with trained peer leaders for 6 months. After the DSMS sessions, the group will transition into 6 months of ongoing support and will be encouraged to continue DSMS through initiatives that are important to them.

Behavioral: Peer Led Diabetes Self-Management Support
While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.

Behavioral: Diabetes Self-Management Education
Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.

Active Comparator: Control Group

Participants in the control group will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist.

Behavioral: Diabetes Self-Management Education
Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.

Outcome Measures

Primary Outcome Measures

  1. Change in Hemoglobin A1c [baseline, 3-months, 9-months, 15-months]

    Anthropometric/clinical data

  2. Change in Regimen Adherence [baseline, 3-months, 9-months, 15-months]

    Survey data

Secondary Outcome Measures

  1. Change in Depression [baseline, 3-months, 9-months, 15-months]

    survey data

  2. Change in Body Mass Index [baseline, 3-months, 9-months, 15-months]

    Anthropometric data/clinical data

  3. Change in Blood Pressure [baseline, 3-months, 9-months, 15-months]

    Anthropometric data/clinical data

  4. Change in Diabetes Social Support [baseline, 3-months, 9-months, 15-months]

    survey data

  5. Change in Diabetes-Related Distress [baseline, 3-months, 9-months, 15-months]

    survey data

  6. Change in Diabetes Quality of Life [baseline, 3-months, 9-months, 15-months]

    survey data

  7. Change in Adherence to gender norms [baseline, 3-months, 9-months, 15-months]

    survey data

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Black/African American males, age 21 years or older with diagnosis of T2D for six months, transportation to attend program activities, under the care of a physician for diabetes, and willing to attend group delivered sessions.
Exclusion Criteria:
  • We considered restricting eligibility to a higher-risk population of participants with A1c ≥ 8%. Preliminary data suggest that over 50% of the proposed study sample will have an A1c ≥ 8%. Focusing on all older Black men with T2D allows us to cast a wide net for secondary prevention and public health impact.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Jaclynn Hawkins, PhD, University of Michigan, School of Social Work

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jaclynn Hawkins, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier:
NCT05370781
Other Study ID Numbers:
  • HUM00200469
First Posted:
May 12, 2022
Last Update Posted:
Jun 8, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 8, 2022